WO2007037601A1 - Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof - Google Patents

Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof

Info

Publication number
WO2007037601A1
WO2007037601A1 PCT/KR2006/003728 KR2006003728W WO2007037601A1 WO 2007037601 A1 WO2007037601 A1 WO 2007037601A1 KR 2006003728 W KR2006003728 W KR 2006003728W WO 2007037601 A1 WO2007037601 A1 WO 2007037601A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
cells
present
seq
metastasis
Prior art date
Application number
PCT/KR2006/003728
Other languages
French (fr)
Inventor
Jang-Hee Hahn
Kyoung-Jin Lee
Dong-Min Kang
Original Assignee
Knu-Industry Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020050090668A external-priority patent/KR100758006B1/en
Priority claimed from KR1020060060890A external-priority patent/KR100793947B1/en
Priority claimed from KR1020060067440A external-priority patent/KR100793949B1/en
Application filed by Knu-Industry Cooperation Foundation filed Critical Knu-Industry Cooperation Foundation
Priority to US11/991,310 priority Critical patent/US8207128B2/en
Publication of WO2007037601A1 publication Critical patent/WO2007037601A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Definitions

  • control peptide is a peptide consisting of EEFD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.

Description

Description
POLYPEPTIDE INHIBITING TRANSMIGRATION OF
LEUKOCYTES OR GROWTH AND/OR METASTASIS OF
CANCER CELLS, AND FUSION PROTEIN THEREOF
Technical Field
[1] The present invention relates to a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also relates to a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof. Background Art
[2] An inflammatory response is known as a protective response of living organism for rehabilitating the structures and functions of tissues damaged by infection, trauma, etc. Mobilization of leukocytes to a focus of inflammation is critical for the rapid resolution of infections and restoration of tissue damages resulting from a variety of injuries. However, a misdirected or prolonged inflammatory response causes damage to the body's tissues or diseases. For example, inflammatory diseases are caused by bacterial or viral infection, e.g., cerebrospinal meningitis, enteritis, dermatitis, uveitis, encephalitis, or adult respiratory distress syndrome, or non-infectious factors, e.g., trauma, autoimmune diseases, or organ transplantation rejection. Inflammatory diseases are classified into acute and chronic inflammatory diseases according to symptoms or pathological features. Acute inflammation such as allergy or bacterial/ viral infection is manifested as local signs such as a change in bloodstream, blood vessel size, and vascular permeability, and the recruitment of leukocytes. In contrast, a main pathological feature of chronic inflammation such as rheumatoid arthritis, artherosclerosis, chronic kidney infection, or hepatocirrhosis is a continuous emigration of macrophages, lymphocytes, or plasma cells into foci of inflammation due to recurrence of inflammatory factors, thereby causing a long-lasting inflammatory response.
[3] In order to induce an inflammatory response, the emigration of leukocytes into inflammation foci is an essential event. Many cell adhesion molecules are implicated in the emigration of leukocytes. That is, the emigration of leukocytes includes a rolling stage in which leukocytes are mobilized to the blood vessels of inflamed sites by chemokine secreted from the inflamed sites and then rolled on surfaces of vascular endothelial cells while reducing the velocity of cell movement; an adhesion stage in which the leukocytes stops rolling and are firmly adhered to the vascular endothelial cells; and a transmigration stage wherein the leukocytes migrate through capillary vessels and basement membranes. The final stage, i.e., the transmigration stage is also called "diapedesis" or "transendothelial migration".
[4] Cancer cells induced by carcinogens proliferate rapidly relative to normal cells, thereby forming tumor masses, invading surrounding tissues, and interfering with normal body functions. Cancer cells bring nutrients and oxygen by inducing an- giogenesis, and metastasis thereof is also caused by angiogenesis. Although cancer cells grow infinitely at specific sites, they can also leave the sites from which they originated, migrate to and grow in new sites, whose process is called "metastasis". Metastasis involve several key steps: conversion of cancer cells to migratory mesenchymal cells, dissociation of the mesenchymal cells from the original tumor sites, invasion into and spread through surrounding connective tissues and capillary vessels, migration through blood vessels, escape from the blood vessels, migration through connective tissues, and proliferation in secondary sites.
[5] Expression and activation of cell adhesion molecules on surfaces of tumor cells play a very important role in tumor metastasis (Zetter, B. R. (1993). Adhesion molecules in tumor metastasis. Semin Cancer Biol. 4: 219). Tumor metastasis is induced by regulating the expression pattern and activity of cell adhesion molecules on surfaces of tumor cells. In order to understand the metastasis of tumor cells, it is prerequisite to understand cell adhesion molecules and substances for regulating the expression and functions of the cell adhesion molecules (Bailly, M., Yan, L., Whitesides, G. M., Condeelis, J. S., and Segall, J. E. (1998). regulation of Protusion Shape and Adhesion to the sustratum during chemoacic esponses of mammalian carcinoma cells. Exp Cell Res. 241: 285; Frisch, S. M., Vuori, K., Ruoslahti, E., and Chan-HuL, P. (1996). Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793; and Hannigan, G. E., Leung-Hagesteijn, C. , Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C, and Dedhar, S. (1996). Regulation of cell adhesion and anchorage-dependent growth by a new βl-integrin-linked protein kinase. Nature 379: 91).
[6] Meanwhile, the present inventors have disclosed that CD99 (MIC2) molecule, which is one of the transmembrane proteins, regulates an intercellular adhesion by regulating a cell surface expression of LFA-I (Hahn, J. H., Kim, M. K., Choi, E. Y., Kim, S. H., Sohn, H. W., Ham, D. I., Chung, D. H., Kim, T. J., Lee, W. J., Park, C. K., Ree, H. J., and Park, S. H. (1997) CD99 (MIC2) regulates the LFA- 1/ICAM-l -mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J. Immunol. 159: 2250). CD99 is a type I transmembrane protein composed of a glycosylated extracellular domain, a transmembrane domain, and a short intracellular domain (Banting, G. S., Pym, B., Darling, S. M., and Goodfellow P. N. (1989). The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein. MoI. Immunol. 26: 181). Although there has not been much research about the function of the CD99 molecule, it has been presumed that the CD99 molecule is associated with cell adhesion, on the basis of the observations that the engagement of the CD99 molecule with anti-CD99 monoclonal antibody induces homotypic cell aggregation of various lymphoid cell lines as well as double-positive thymocytes (Bernard, A., Aubrit, F., Raynal, B., Pham, D., and Boumsell, L. (1988). A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J Immunol 140: 1802; and Bernard, G., Zoccola, D., Deckert, M., Breittmayer, J., Aussel, C, and Bernard. A.(1995). The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes. J. Immunol. 154: 26).
[7] The present inventors have found that CD99 is involved in the migration of monocytes through connective tissues (Kim YK., 2004. Regulation of MMP-9 gene expression by CD99 type II in the monocytes. Kangwon National University). The present inventors have also disclosed that when CD99 is activated, the function of β integrin is altered, thereby preventing the adhesion of cancer cells onto extracellular matrices (ECMs). This suggests that CD99 may be involved in metastasis of cancer cells (Suh JS., 2001. Control of invasiveness of human breast carcinoma cell line MCF-7 by CD99 molecule. Kangwon National University). In addition, Muller WA et al. have disclosed that inflammatory diseases can be cured by inhibiting the CD99-mediated transmigration of leukocytes (Schenkel AR, Mamdouh Z, Chen X, Lieman RM, Muller WA (2002) CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 3:143; and US. Patent Publication No. 2003/0211099). Disclosure of Invention Technical Problem
[8] The present inventors have found that a polypeptide having an amino acid sequence derived from CD99 can prevent the transmigration of leukocytes or the growth and/or metastasis of cancer cells.
[9] Therefore, the present invention provides a polypeptide derived from CD99, inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, and a fusion protein thereof. [10] The present invention also provides a polynucleotide encoding the polypeptide and a vector including the polynucleotide.
[11] The present invention also provides a transformant obtained by transforming a host cell with the vector.
[12] The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, including the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[13] The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, including the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier. Technical Solution
[14] In accordance with an aspect of the present invention, there is provided a polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells.
[15] In accordance with another aspect of the present invention, there is provided a fusion protein wherein a polyhistidine (poly-His) region is fused to the polypeptide.
[16] In accordance with still another aspect of the present invention, there is provided a polynucleotide encoding the polypeptide.
[17] In accordance with still another aspect of the present invention, there is provided a vector comprising the polynucleotide encoding the polypeptide.
[18] In accordance with still another aspect of the present invention, there is provided a transformant obtained by transforming a host cell with the vector.
[19] In accordance with yet another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[20] In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier. Brief Description of the Drawings
[21] FTG. 1 illustrates the structures of polypeptides as set forth in SEQ ID NOs: 2-9;
[22] FIGs. 2 and 3 are graphs illustrating effects of polypeptides of the present invention on the transmigration of a human monocyte cell line, U937;
[23] FIG. 4 is a graph illustrating effects of polypeptides of the present invention on rheumatic inflammation of mice having collagen-induced arthritis; [24] FlG. 5 shows the degree of corrosion of articular cartilages of a control group and a test group treated with a polypeptide of the present invention; [25] FlG. 6 is a graph illustrating cell numbers of transmigrated lymphocytes and myeloid cells in the spleens of a control group and a test group treated with a polypeptide of the present invention; [26] FlG. 7 is a graph illustrating cell numbers of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) migrated into the joint spaces of a control group and a test group treated with a polypeptide of the present invention; [27] FlGs. 8 and 9 are graphs illustrating expression levels of TNF-α and IFN-γin the sera of a control group and a test group treated with a polypeptide of the present invention; [28] FlGs. 10 and 11 are graphs illustrating effects of polypeptides of the present inventi on on adhesion of HUVEC (Human Umbilical Vein Endothelial Cell) to fibronectin; [29] FlG. 12 is inverted microscopic images showing effects of polypeptides of the present invention on bFGF-induced tube formation; [30] FlG. 13 is images showing degree of development of melanoma (A) and degree of angiogenesis (B) in a control group and a test group treated with a polypeptide of the present invention; [31] FlG. 14 is a graph illustrating melanoma tumor volumes in a control group and a test group treated with a polypeptide of the present invention; [32] Fig. 15 is a graph illustrating transendothelial migration assays for MCF-7 human breast carcinoma cells after administration of a polypeptide of the present invention; [33] FlG. 16 is a graph illustrating invasion assay for MCF-7 human breast carcinoma cells after administration of a polypeptide of the present invention; [34] FlG. 17 is images (A) showing nodules of melanoma cells that have spread to the lungs and liver through transmigration after administration of a polypeptide of the present invention and a graph (B) illustrating the number of the nodules.
Mode for the Invention [35] Throughout the specification, the term "inflammatory diseases" include acute and/or chronic inflammatory diseases, e.g., rheumatoid arthritis, adhesive capsulitis, sinovitis, coxarthritis, osteoarthritis, osteoporosis, periarthritis, multiple sclerosis, osteomyelitis, systemic lupus erythematosus, polymyalgia rheumatica(PMR), Sjogren's Syndrome, progressive systemic sclerosis(scleroderma), ankylosing spondylitis, polymyositis, der- matomyositis, pemphigus, pemphigoid, Type I diabetes mellitus, myasthenia gravis,
Hashimoto's thyroditis, Graves' disease, Goodpasture's disease, mixed connective tissue disease, sclerosing cholangitis; inflammatory bowel disease such as Crohn's Disease or ulcerative colitis, inflammatory dermatoses; inflammatory respiratory diseases such as usual interstitial pneumonitis(UIP), lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, desquamative interstitial pneumonia, asbestosis, silicosis, berylliosis, talcosis, pneumoconiosis, Adult Respiratory Distress Syndrome, extrinsic allergic alveolitis; immediate hypersensitivity reactions such as asthma or hayfever; sarcoidosis, Wegener's granulomatosis, various angiitis, chronic active hepatitis, delayed-type hypersensitivity reactions such as poison ivy dermatitis, cutaneous allergies, psoriatic arthritis, Reiter's syndrome, immediate hypersensitivity reactions, rheumatic fever, acute or chronic glomerulonephritis, acute exacerbations, pyelonephritis, cellulitis, cystitis, acute cholecystitis, inflammatory aortic aneurysm, atherosclerosis, Still's diseas), Parkinson's disease, Alzheimer's disease. A polypeptide or fusion protein of the present invention can also be administered to patients suffering from diseases involving inflammatory diseases, e.g., reperfusion injuries, autoimmune diseases, organ transplantation rejection or tissue allograft organ rejection, etc. Thus, the "inflammatory diseases" as used herein are meant to comprehend diseases involving inflammatory diseases. A polypeptide or fusion protein of the present invention can be used in rheumatoid arthritis, osteoporosis, respiratory inflammation, autoimmune diseases, and/or organ transplantation rejection, particularly preferably, rheumatoid arthritis, autoimmune diseases, and/or organ transplantation rejection.
[36] The present inventors have made searches for ligand(s) capable of activating a
CD99 molecule having an amino acid sequence as set forth in SEQ ID NO: 1. In view that CD99 itself acts as a ligand recognizing a CD99 molecule that is a transmembrane protein, ligands of various lengths were made from CD99 molecule and searches were made using the ligands.
[37] Surprisingly, the present inventors found that polypeptides having certain amino acid sequences derived from CD99 could show anti-inflammatory activity by blocking the transmigration of leukocytes through high-affinity binding to vascular endothelial cells and leukocytes. When the polypeptides were injected into inflamed sites of mice with arthritis, an arthritis index and the transmigration of lymphocytes and granulocytes related thereto were significantly reduced, as compared with control mice. Those results show that the polypeptides have preventive or treatment activity for inflammatory responses.
[38] Furthermore, the present inventors found that polypeptides having the amino acid sequences derived from CD99 could inhibit the growth and/or metastasis of cancer cells by inhibiting angiogenesis through high-affinity binding to surfaces of vascular endothelial cells and inhibiting the migration and transmigration of cancer cells through binding to the cancer cells. When the polypeptides were administered to affected sites of mice with melanoma, tumor growth and metastasis were significantly reduced as compared with control mice. Those results show that the polypeptides have inhibitory activity for the growth and/or metastasis of cancer cells.
[39] The present invention provides a polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells. The polypeptide may be selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 2-8. More preferably, the polypeptide may be selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 9-11 and 13-16.
[40] The present invention also provides a fusion protein wherein a polyhistidine
(poly-His) region is fused to the polypeptide. The poly-His region, which is a tag polypeptide, can be used for the separation and purification of the polypeptide of the present invention by binding to a histidine binding resin. In the fusion protein of the present invention, the poly-His region may have an amino acid sequence as set forth in SEQ ID NO: 17.
[41] The present invention also provides a polynucleotide encoding the polypeptide. The polynucleotide can be prepared using a known method in the art. The polynucleotide may have a nucleotide sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 18-20 and 22-25.
[42] The present invention also provides a vector comprising the polynucleotide encoding the polypeptide. Various known cloning vectors, e.g., pPICZα A, B, or C (Invitrogen, U.S.A.), may be used as a cloning vector. Preferably, a vector including DNA encoding a poly-His region, e.g., a pET28a(+) vector (Novagen, U.S.A.) may be used as a cloning vector. The vector of the present invention can be constructed by inserting the polynucleotide encoding the polypeptide into a cloning vector with an appropriate restriction enzyme site using a method commonly known in the art. The vector of the present invention may be directly used in a gene therapeutic composition for the purpose of gene therapy or may be used in the production of transformants.
[43] The present invention also provides a transformant obtained by transforming a host cell with the vector. The host cell is not particularly limited as long as the polypeptide can be effectively expressed. Preferably, the host cell may be selected from microorganisms belonging to the genus Escherichia (e.g., Escherichia coli), the genus Pichia (e.g., X-33 Pichia; Invitrogen, U.S.A.), etc.
[44] The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[45] The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising the polypeptide or its fusion protein as an active ingredient and a pharmaceutically acceptable carrier.
[46] The pharmaceutical compositions of the present invention may include excipients such as lactose or corn starch, lubricants such as magnesium stearate, currently available emulsifiers, suspending agents, buffers, isotonic agents, etc. The pharmaceutical compositions of the present invention can be administered orally or par- enterally. Preferably, the pharmaceutical compositions of the present invention can be formulated into parenteral dosage forms. For intramuscular, intraperitoneal, subcutaneous, or intravenous administration, a sterilized solution of an active ingredient is generally prepared. In this case, the sterilized solution may include a buffer to achieve a desired pH value. With respect to formulations for intravenous administration, an isotonic agent may be used to render the formulations isotonic. The pharmaceutical compositions of the present invention can be formulated into aqueous solutions including a pharmaceutically acceptable carrier such as a saline of pH 7.4. The aqueous solutions can be introduced into a patient's intramuscular blood stream by local bolus injection.
[47] The pharmaceutical composition of the present invention can be administered to patients who suffer from inflammatory diseases, solid cancer (breast cancer, gastric cancer, large bowel cancer, colon cancer, rectal cancer, pancreatic cancer) or lymphoma at a daily dosage of about 0.01 to 10 mg/kg. An adequate dosage is generally determined according to age, body weight, and conditions of a patient.
[48] Hereinafter, the present invention will be described more specifically by the following working examples. However, the following working examples are provided only for illustrations and thus the present invention is not limited to or by them.
[49]
[50] Example 1: synthesis of polypeptides
[51] cDNA fragments of SEQ ID NOs: 18-22 encoding respective polypeptides of SEQ
ID NOs: 9-13 were inserted into pET28a(+) vectors carrying cDNAs encoding the Fc regions of human immunoglobulin to produce five types of pET28a-hCD99-Fc vectors. That is, the cDNA fragments of SEQ ID NOs: 18-22 were isolated by PCR, digested with EcoRI, and inserted into the EcoRI sites of pET28a(+) vectors with ligation enzymes to produce the five types of the pET28a-hCD99-Fc vectors.
[52] Colonies obtained by transforming BL21(DE3) cells with the expression vectors, pET28a-hCD99-Fc, were cultured in LB media for about 4-6 hours. When the absorbance (A600) of the cultures reached 0.4-0.6, protein expression was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) (1.4 mM) for 7-9 hours. The cells were precipitated by centrifugation, washed with phosphate buffered saline (PBS), and precipitated to remove impurities from the media. Fractions were analyzed by SDS-PAGE gel to check protein expression.
[53] For purification of expressed proteins, an 8M urea buffer (8M urea, 0.01M Tris-Cl,
0.1M NaH PO ) was used. The pH of the urea buffer was adjusted to 8.0, 6.3, 4.5, etc. according to a purification step. The cells were lysed with a pH 8.0 urea buffer containing protease inhibitors (1 mM PMSF, 10 D/D leupeptin, 1 D/D, pepstatin, 1 D/D aprotinin) and centrifuged at 13,000 rpm for 20 minutes at 4 °C. The supernatants were mixed with histidine (His)-binding resins (Ni-NTA His Bind Resins, Novagen, U.S. A.) in a 1 D Eppendorf tube, and the mixtures were incubated at 4 °C for 16 hours to induce the binding of histidine residues of the expressed proteins with the His-binding resins. The reaction solutions were centrifuged, the supernatants were discarded, and the pellets were washed with a pH 6.3 urea buffer. The protein was then eluted with a pH 4.5 urea buffer, dialyzed against PBS, and stored in aliquots in a cold store.
[54] Polypeptides of SEQ ID NOs: 14-16 were synthesized with an automatic peptide synthesizer (PeptrEx-R48, Peptron, Daejeon, Korea) using a FMOC solid-phase method. The synthesized polypeptides were purified and analyzed by reverse-phase high-performance liquid chromatography (reverse-phase HPLC) (Prominence LC- 20AB, Shimadzu, Japan) using a C18 analytical RP column (Shiseido capcell pak), and isolated using a mass spectrometer (HP 1100 Series LC/MSD, Hewlett-Packard, Roseville, U.S.A.). For optimization of Experimental Examples 2, 3, 8, and 11 using mice as an experimental animal, a polypeptide derived from the mouse CD99 (SEQ ID No: 26) was also synthesized with the same methods in the above. The polypeptide of SEQ ID No: 26 corresponds to the polypeptide of SEQ ID No: 14 derived from human CD99.
[55] The structures of polypeptides as set forth in SEQ ID NOs: 9-16 are illustrated in
FIG. 1.
[56]
[57] Example 2: preparation of polypeptide-containing compositions
[58] The polypeptides of SEQ ID NOs: 9-13 were dissolved in PBS to a concentration of
3 D/100 D. Also, the polypeptides of SEQ ID NOs: 14-16 and 26 were dissolved in dimethylsulfoxide (DMSO) to a concentration of 3 D/D, and a saline solution was added thereto so that the concentration of each polypeptide was 20 D, 40 D, 80 D, or 100 D based on the volume (100 D) of the final solution. The resultant protein solutions were used in the following experimental examples.
[59]
[60] Experimental Example 1: tests for inhibitory activity of polypeptides of the present invention against transmigration of monocytes
[61] Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in the upper compartments of Boy den chambers. The supernatants were removed, and human monocytes (U937), which had been untreated or treated with the compositions prepared in Example 2, were seeded at 5 x 105 cells/chamber. At this time, a culture including a chemo-attractant (a supernatant obtained by centrifugation of a culture obtained after culturing NIH/3T3 mouse fibroblasts in serum-free DMEM containing 0.005% vitamin C and 0.1% Bovine Serum Albumin (BSA) for 16 hours) was placed in the lower compartments of the chambers to induce the invasion of the monocytes. The chambers were incubated for 6 hours, and the number of the cells migrated to the lower compartments was measured. The test was repeated five times, and the results are illustrated in FIGs. 2 and 3. In FIG. 3, the "control peptide" is a peptide consisting of EEFD.
[62] Referring to FIGs. 2 and 3, the number of migrated monocytes in the test groups treated with polypeptides according to the present invention was significantly reduced (about 2/3 reduction) as compared with that in the control group.
[63]
[64] Experimental Example 2: tests for inhibitory activity of polypeptides of the present invention against arthritis
[65] Effects of polypeptides of the present invention on rheumatoid arthritis (RA), one of representative inflammatory diseases, were tested. Type II collagen (10 mg/kg) was injected into mice (8-12 weeks old) to induce RA. A solution of a polypeptide of SEQ ID NO: 26 (40 or 80 D) in a saline solution (100 D) was intraperitoneally administered to the mice with RA at 2-day intervals (100 D for each) for four weeks. As control groups, a saline solution (100 D) or a solution of methotrexate (MTX, 100 D) used as an antiinflammatory agent in a saline solution (100 D) was intraperitoneally administered to the mice with RA.
[66] The onset and severity of arthritis in each experimental group were visually determined, and the arthritis index was measured using a method known in the art (SI Lee, PM Hyun, SH Kim, KS Kim, SK Lee, BS Kim, PJ Maeng, and J-S Lim (2005) Suppression of the Onset and Progression of Collagen-Induced Arthritis by Chebulagic Acid Screened From a Natural Product Library. Arthritis Rheum 52: 345). The results are illustrated in FIG. 4. In FIG. 4, CIA represents collagen-induced arthritis. Referring to FIG. 4, in the test groups treated with the polypeptide of the present invention, arthritis indices began to decrease 2 weeks after the polypeptide treatment. At 4 weeks after the polypeptide treatment, the arthritis indices were reduced to about 1/3 of those of the control groups.
[67] Meanwhile, the degree of corrosion of articular cartilages of normal mice with no
RA and the above CIA mice was measured. That is, the knee joint tissues of the hind legs of the normal mice with no RA, saline-treated CIA mice, MTX-treated CIA mice, and CIA mice treated with a solution of a polypeptide of SEQ ID NO: 26 (80 D) in a saline solution (100 D) were harvested. The harvested tissues were fixed in 10% formalin, decalcified with 5% formic acid, processed into paraffin blocks, cut into 5 D sections, and stained with haematoxylin and eosin or Masson's trichrome, and examined with a microscope (at 20Ox magnification). The results are shown in FlG. 5.
[68] Referring to FlG. 5, severe corrosion and invasion of leukocytes were observed in the articular cartilages of the CIA mice, as compared with the normal mice. In contrast, corrosion of articular cartilages and invasion of leukocytes in the CIA mice treated with the polypeptide of SEQ ID NO: 26 according to the present invention were diminished to the extent that was observed in the normal mice and the MTX-treated CIA mice.
[69]
[70] Experimental Example 3: tests for inhibitory activity of polypeptides of the present invention against transmigration of lymphocytes and myeloid cells in the spleens
[71] A polypeptide of SEQ ID NO: 26 (40 D/100D) was intraperitoneally administered to mice with RA, which had been induced in the same manner in Experimental Example 2, at 2-day intervals for 4 weeks. Normal mice, saline-treated RA mice with intraperitoneal injection of a saline solution, and MTX-treated RA mice with intraperitoneal injection of a solution of MTX (100 D) in a saline solution (100 D) were used as control groups. Spleen tissues were harvested from the mice of all the experimental groups and washed with RPMI 1640 media, and single cells were isolated. After the total number of the single cells were counted, the single cells were stained with monoclonal antibodies (anti-CD3\ CD4+, CD8+, CDlIb+, CD19\ CD69+, Gr-I+) capable of labeling T cells (CD3+, CD4+, CD8+), activated T cells (CD3+, CD69+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+), and flow cytometry analysis was performed. The number of lymphocytes and myeloid cells migrated to joint spaces was measured by determining the number of the T cells, the activated T cells, the B cells, and the myeloid cells per total cell number, and the results are illustrated in FlG. 6.
[72] Referring to HG. 6, the migrated cell numbers for the T cells (CD3+, CD4+, CD8+), the activated T cells (CD3+, CD69+), the B cells (CD19+), and the myeloid cells (CDl Ib+, Gr-I+) in the test group treated with the polypeptide according to the present invention were similar to those of the MTX-treated group, and were reduced to about 2/3 of those of the saline-treated group.
[73]
[74] Experimental Example 4: tests for inhibitory activity of polypeptides of the present invention against migration of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) into the joint spaces
[75] As well known, when inflammation develops in joints, lymphocytes and myeloid cells of different differentiation stages invade joint spaces. Thus, effects of polypeptides according to the present invention on invasion of lymphocytes and myeloid cells into joint spaces were tested.
[76] The polypeptide of the present invention, a saline solution, or MTX was administered to RA mice in the same manner as in Experimental Example 3, and synovial fluid was obtained from the joint spaces of the mice of all the experimental groups. After the total cell number in the synovial fluid was counted, flow cytometry analysis was performed in the same manner as in Experimental Example 3 to measure the number of T cells (CD3+), B cells (CD19+), and myeloid cells (CDlIb+, Gr-I+) migrated to the joint spaces. The results are illustrated in FIG. 7.
[77] Referring to FIG. 7, the number of T cells (CD3+, CD4+, CD8+), B cells (CD19+), and myeloid cells (CDl Ib+, Gr-I+) migrated to joint spaces in the polypeptide-treated group according to the present invention was similar to that of the MTX-treated group and was reduced to about 50-70% of that of the saline-treated group.
[78]
[79] Experimental Example 5: tests for inhibitory activity of polypeptides of the present invention against expression of TNF-αand IFN-γ
[80] When inflammation occurs, invasion of T cells into peripheral lymph nodes increases, and the expression levels of TNF-αand INF-γwhich are secreted from the T cells also increase. Thus, effects of polypeptides according to the present invention on the expression of TNF-αand INF-γwere tested.
[81] RA was induced in mice in the same manner as Experimental Example 2, and a saline solution, MTX, or a polypeptide according to the present invention was administered to the RA mice. Then, sera were isolated from all the experimental groups, and the expression levels of TNF-αand INF-γwere measured using ELISA. The results are illustrated in FIGs. 8 and 9.
[82] Referring to FIGs. 8 and 9, the expression levels of TNF-αand INF-γ in the polypeptide-treated group according to the present invention were similar to those of the MTX-treated group and were reduced to about 50% of those of the saline-treated group.
[83]
[84] Experimental Example 6: tests for inhibitory activity of polypeptides of the present invention against adhesion of HUVEC to extracellular matrix
[85] Effects of polypeptides of SEQ ID NOs: 9-16 on adhesion of HUVEC to fibronectin were tested.
[86] Each well of a 96-well culture plate was coated with fibronectin, a component of extracellular matrix, for 6 hours under UV light, and then blocked with 1% heat- inactivated BSA for 1 hour. HUVEC cells (5 x 10 ) were dispensed into each well, and then the protein solution prepared in Example 2 was added to the well. After incubation in 5% CO at 37 °C for 1 hour, the cells were gently washed three times with PBS, and then detached using trypsin-EDTA and stained with a trypan-blue solution. The number of the cells was determined using a hemacytometer. The results are illustrated in FIGs. 10 and 11.
[87] Referring to FIGs. 10 and 11, in the test groups treated with the polypeptides of the present invention, the number of HUVECs adhered to fibronectin was reduced by about 10-40% relative to a control group. However, in the test group treated with the polypeptide of SEQ ID NO: 12 including no amino acids at positions 94-97 of SEQ ID NO: 1, the degree of adhesion of HUVECs to fibronectin was similar to that of the control group. Thus, it is anticipated that polypeptides of the present invention including peptides at positions 94-97 of SEQ ID NO: 1 can inhibit angiogenesis.
[88]
[89] Experimental Example 7: tests for inhibitory activity of polypeptides of the present invention against in vitro tube formation
[90] Interactions of basement membrane components of blood vessels with vascular endothelial cells play an important role in formation and maintenance of new blood vessels. Thus, effects of polypeptides of the present invention on tube formation were evaluated.
[91] HUVECs were plated at a density of 8 x 104 cells/well to each well of 24- well culture plates coated with Matrigel. The protein solution including the polypeptide of SEQ ID NO: 9 (30 D/D) prepared in Example 2, secondary antibody (Goat anti-mouse IgG; Dinona, Korea), or a mixture thereof was added to the wells, and the cells were cultured in media 199 containing 20% fetal bovine serum (FBS), penicillin (100 units/ D), streptomycin (100 WIW), bFGF (3 ng/D), and heparin (5 units/D) in aiβ&bator maintained at 5% CO partial pressure and a temperature of 37 °C for 24 hours. Formation of new blood vessels was examined using an inverted microscope (at 50x magnification), and the results are shown in FIG. 12.
[92] Referring to FIG. 12, when HUVECs were treated with the protein solution including the polypeptide of the present invention, tube formation was significantly reduced.
[93]
[94] Experimental Example 8: tests for inhibitory activity of polypeptides of the present invention against in vivo tumor development and angiogenesis
[95] B16-F10-Luc-G5 (mouse melanoma cell line, Xenogen, U.S.A.) was injected into the subcutaneous fat tissues of the backs of 10 male nude mice (5 weeks old) (1.5 x 10 cells/mouse). At 48 hours after the injection, the mice were divided into five mice for a test group and five mice for a control group. In the test group, a polypeptide (100 D) of SEQ ID NO: 26 was intraperitoneally administered to each mouse at a 48-hour intervals. Tumor cells were injected into the test group and the control group, and from 12 days after the injection of the tumor cells, a tumor volume was measured. The tumor volume was calculated by the formula: (L x W)2 x H x 0.5 where L, W, and H are respectively the length, width, and height of tumor.
[96] At 14 days after the injection of the tumor cells, tumor tissues were excised from the mice, fixed in 4% paraformaldehyde, washed with water, processed into paraffin blocks, cut into 5 D standard frontal sections, and stained with haematoxylin and eosin, and examined with a microscope (at 4Ox magnification) to compare the degree of an- giogenesis.
[97] FIG. 13 is images showing the degree of development of melanoma (A) and the degree of angiogenesis (B) in the control group and the test group treated with the polypeptide of the present invention. Referring to FIG. 13, in the test group treated with the polypeptide of the present invention, the development of melanoma and angiogenesis were significantly reduced as compared with those of the control group.
[98] FIG. 14 is a graph illustrating melanoma tumor volumes in the control group and the test group treated with the polypeptide of the present invention. Referring to FIG. 14, in the test group treated with the polypeptide of the present invention, melanoma volume at 12 days after the injection of the tumor cells was reduced to about 1/6 of that of the control group.
[99]
[100] Experimental Example 9: tests for inhibitory activity of polypeptides of the present invention against in vitro transmigration of cancer cells
[101] Transendothelial migration assays for MCF-7 human breast carcinoma cells were performed in polycarbonate transwell inserts (8-D pore; Costar,Corning, NY) coated with HUVECs and grown as a monolayer for 24 hours. MCF-7 cells were resuspended in serum-free RPMI- 1640and were preincubated with 10 Dof a control peptide consisting of EEFD or 10 D of a peptide of SEQ ID NO: 16 for 1 hour before plating. HUVEC cells were also treated as described above at the same time.Typically, 5 X 105 MCF-7 cells were seeded in the upper compartment, and chemo-attractant (described in Experimental Example 1) was placed in the lower compartment. After 6 hours at 37 °C, the number of MCF-7 cells that had migrated through the monolayer was determinedby direct counting.
[102] FIG. 15 is a graph illustrating the number of transmigrated cells in the experiment described above. Referring to FIG. 15, the number of transmigrated MCF-7 cells in the test groups was reduced to about 60% of that in the control group. Taking into consideration that transmigration is essential for migration of cancer cells into organs through blood vessels, it is anticipated that polypeptides of the present invention can effectively inhibit the migration of cancer cells. [103] [104] Experimental Example 10: tests for inhibitory activity of polypeptides of the present invention against invasion of cancer cells
[105] Cell migration was measured using a Transwell migration apparatus(Costar, Inc.,
Cambridge, United Kingdom). The filters (8-D pore size) were coated with lmg/ml fi- bronectinsolution on top surface. MCF-7 cells were treated with a polypeptide of SEQ ID NO: 14 (10 D, 50 D, 100 D), incubated in a 5% Cfficubator at 37 °C for 1 hour, and then washed with serum-free RPMI- 1640. MCF-7 cells (2.4 x 10 cells) were loaded to the upper chamber of the Transwell, whereas chemo-attractant described above were loaded into the lowerchamber. Cells migrated into the lower chambers of the Transwell were counted three times at 24-hour intervals, and then the results were stastically analyzed.
[106] FIG. 16 is a graph illustrating the number of the human breast cancer cells that have invaded fibronectin after administration of the polypeptide of the present invention. Referring to FIG. 16, in the test groups treated with the polypeptide of the present invention, the invasion rate of the human breast cancer cells was reduced by about 50% relative to that of a control group treated with a peptide consisting of EEFDDAEEFDD. Taking into consideration that cancer cells from blood vessels invade basement membranes or surrounding connective tissues and then spread to secondary sites, it is anticipated that polypeptides of the present invention can effectively inhibit the metastasis of cancer cells.
[107]
[108] Experimental Example 11: tests for inhibitory activity of polypeptides of the present invention against in vivo transmigration of cancer cells
[109] B16-F10-Luc-G5 cells (mouse melanoma cell line, Xenogen, U.S.A.) were injected into the tail veins of 10 nude mice (5 weeks old). The nude mice were divided into five mice for a control group and five mice for a test group. The control group was injected with a mixture of PBS with a peptide consisting of EEFDDAEEFDD (control peptide) and the test group with a mixture of PBS with 100 D of a peptide of SEQ ID NO: 26. The control peptide and the peptide of SEQ ID NO: 26 were intraperitoneally administered to the control group and the test group, respectively, at 2-day intervals for 15 days. Then, the nude mice were dissected and the lungs and livers were excised from the nude mice. Tumor nodules were counted.
[110] FIG. 17 is images (A) showing melanoma nodules that have spread to the lungs and livers of the mice of the control group and the test group through transmigration and a comparative graph (B) illustrating the number of the melanoma nodules. Referring to FIG. 17, the degree of spread of melanoma in the test group treated with the polypeptide of the present invention was reduced to about 40% of that of the control group.
Industrial Applicability A polypeptide or its fusion protein according to the present invention can inhibit the transmigration of leukocytes or the growth and/or metastasis of cancer cells.

Claims

Claims
[I] A polypeptide consisting of 4 - 130 amino acids derived from the peptide of SEQ ID NO: 1, said polypeptide comprising an amino acid sequence from position 94 to position 97 of SEQ ID NO: 1; wherein said polypeptide inhibits transmigration of leukocytes or growth and/or metastasis of cancer cells.
[2] The polypeptide of claim 1, which is selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 2-8.
[3] The polypeptide of claim 1, which is selected from the group consisting of polypeptides as set forth in SEQ ID NOs: 9-11 and 13-16.
[4] A fusion protein wherein a polyhistidine (poly-His) region is fused to the polypeptide of any one of claims 1 through 3.
[5] The fusion protein of claim 4, wherein the poly-His region has an amino acid sequence as set forth in SEQ ID NO: 17.
[6] A polynucleotide encoding the polypeptide of any one of claims 1 through 3.
[7] The polynucleotide of claim 6, which is selected from the group consisting of polynucleotides as set forth in SEQ ID NOs: 18-20 and 22-25.
[8] A vector comprising a polynucleotide encoding the polypeptide of any one of claims 1 through 3.
[9] The vector of claim 8, wherein a cDNA encoding a poly-His region is inserted.
[10] A transformant obtained by transforming a host cell with the vector of claim 8.
[II] The transformant of claim 10, wherein the host cell is selected from cells of microorganisms belonging to the genus Escherichia and the genus Pichia.
[12] A pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising the polypeptide of any one of claims 1 through 3 as an active ingredient and a pharmaceutically acceptable carrier.
[13] A pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising, as an active ingredient, a fusion protein wherein a poly-His region is fused to the polypeptide of any one of claims 1 through 3, and a pharmaceutically acceptable carrier.
[14] A pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising the polypeptide of any one of claims 1 through 3 as an active ingredient and a pharmaceutically acceptable carrier.
[15] A pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells, comprising, as an active ingredient, a fusion protein in which a poly-His region is fused to the polypeptide of any one of claims 1 through 3, and a pharmaceutically acceptable carrier.
PCT/KR2006/003728 2005-09-28 2006-09-20 Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof WO2007037601A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/991,310 US8207128B2 (en) 2005-09-28 2006-09-20 Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR1020050090668A KR100758006B1 (en) 2005-09-28 2005-09-28 Polypeptide having inhibitory activity for angiogenesis and inflammation and a pharmaceutical composition comprising the polypeptide
KR10-2005-0090668 2005-09-28
KR1020060060890A KR100793947B1 (en) 2006-06-30 2006-06-30 Polypeptides or fusion proteins thereof having an inhibitory activity against growth and metastasis of cancer cells
KR10-2006-0060890 2006-06-30
KR1020060067440A KR100793949B1 (en) 2006-07-19 2006-07-19 Polypeptides or fusion proteins thereof having preventive or treating activity against inflammatory diseases
KR10-2006-0067440 2006-07-19

Publications (1)

Publication Number Publication Date
WO2007037601A1 true WO2007037601A1 (en) 2007-04-05

Family

ID=37899983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/003728 WO2007037601A1 (en) 2005-09-28 2006-09-20 Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof

Country Status (2)

Country Link
US (1) US8207128B2 (en)
WO (1) WO2007037601A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049289A2 (en) 2009-10-23 2011-04-28 (주) 수파드엘릭사 Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
ITMI20091994A1 (en) * 2009-11-13 2011-05-14 Istituto Ortopedico Rizzoli ANTICORPAL FRAGMENT OF THE SINGLE CHAIN VARIABLE REGION (SCFV) ABLE TO RECOGNIZE AND BIND THE HUMAN PROTEIN CD99
WO2021118212A1 (en) * 2019-12-11 2021-06-17 강원대학교산학협력단 Pharmaceutical composition comprising peptide that inhibits interaction of p53 and foxo4

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102297396B1 (en) * 2020-07-29 2021-09-06 (주)티카로스 Immune Synapse-Stabilizing Chimeric Antigen Receptor(CAR) T Cell

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402530A1 (en) * 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2001055208A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1436318A2 (en) * 2001-09-05 2004-07-14 Enkam Pharmaceuticals A/S Ncam binding compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402530A1 (en) * 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENPEPT [online] 2 June 1997 (1997-06-02), XP003008891, Database accession no. (AAB58501) *
SCHENKEL A.R. ET AL.: "CD99 plays a major role in the migration of monocytes through endothelial junctions", NAT. IMMUNOL., vol. 3, no. 2, February 2002 (2002-02-01), pages 143 - 150, XP009006021 *
SCOTLANDI K. ET AL.: "CD99 engagement: an effective therapeutic strategy for Ewing tumors", CANCER RES., vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5134 - 5142, XP003008890 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049289A2 (en) 2009-10-23 2011-04-28 (주) 수파드엘릭사 Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
EP2491944A2 (en) * 2009-10-23 2012-08-29 Supadelixir Inc. Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
CN102711792A (en) * 2009-10-23 2012-10-03 舒帕得力克瑞股份有限公司 Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
JP2013507954A (en) * 2009-10-23 2013-03-07 スパデリクサー インコーポレイテッド Polypeptide or fusion protein thereof that suppresses leukocyte extravasation or cancer cell growth and / or metastasis
EP2491944A4 (en) * 2009-10-23 2013-09-11 Supadelixir Inc Polypeptide or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis of cancer cells
EP2692353A2 (en) 2009-10-23 2014-02-05 Supadelixir Inc. Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis
EP2692353A3 (en) * 2009-10-23 2014-03-26 Supadelixir Inc. Peptide LGD or fused protein thereof inhibiting the extravasation of white blood cells or the growth and/or metastasis
ITMI20091994A1 (en) * 2009-11-13 2011-05-14 Istituto Ortopedico Rizzoli ANTICORPAL FRAGMENT OF THE SINGLE CHAIN VARIABLE REGION (SCFV) ABLE TO RECOGNIZE AND BIND THE HUMAN PROTEIN CD99
WO2011058517A1 (en) * 2009-11-13 2011-05-19 Istituto Ortopedico Rizzoli Single-chain variable fragment (scfv) able to recognize and bind cd99 human protein
US8710194B2 (en) 2009-11-13 2014-04-29 Istituto Ortopedico Rizzoli Single-chain variable fragment (scFv) able to recognize and bind CD99 human protein
WO2021118212A1 (en) * 2019-12-11 2021-06-17 강원대학교산학협력단 Pharmaceutical composition comprising peptide that inhibits interaction of p53 and foxo4

Also Published As

Publication number Publication date
US20100286064A1 (en) 2010-11-11
US8207128B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
US5928893A (en) Monoclonal antibody specific for human 4-1BB and cell line producing same
AU710160B2 (en) Cytokine designated Lerk-7
US7750138B2 (en) Angiogenesis-inhibiting chimeric protein and the use
CA2059124C (en) Platelet aggregation inhibitors
US5668104A (en) Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a growth factor, and methods employing them in vitro or in vivo
US5840869A (en) DNA encoding interleukin-4 receptors
US7659385B2 (en) Polynucleotides encoding molecules designated LDCAM
EP1375518B1 (en) Anti-osteopontin antibody and use thereof
Pochon et al. Demonstration of a second ligand for the low affinity receptor for immunoglobulin E (CD23) using recombinant CD23 reconstituted into fluorescent liposomes.
NZ297530A (en) Cyclic peptides that inhibit the interaction of vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with integrin very late antigen 4 (VLA-4)
JPH08505628A (en) Peptide type cell adhesion inhibitor
US8207128B2 (en) Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
US8530421B2 (en) Isolated polypeptides used for treatment of inflammatory diseases and inhibiting cancer metastasis
JP2002528389A (en) Anti-inflammatory peptides derived from IL-2 and analogs thereof
CN105916883B (en) Bifunctional fusion proteins and its preparation method and application
MXPA03003008A (en) Chemokine mutants in the treatment of multiple sclerosis.
US20110189181A1 (en) Use of agents derived from CEACAM1 for the treatment of inflammatory diseases
WO1996022106A1 (en) Cd8 antagonists
CA1280379C (en) Peptides and compositions
KR100793949B1 (en) Polypeptides or fusion proteins thereof having preventive or treating activity against inflammatory diseases
WO1994009132A1 (en) Human cd26 and methods for use
JP2003518940A (en) Nucleic acids encoding (poly) peptides having CHIPS activity
US20100197576A1 (en) Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells
JP2003500055A (en) IL-1 eta DNA and polypeptides
WO1996040774A1 (en) Complexes of modified lymphotoxins as pharmaceutical preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11991310

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06798811

Country of ref document: EP

Kind code of ref document: A1